BPM31510 Administered Intravenously With Gemcitabine In Advanced Pancreatic Cancer Patients

Study Overview

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line therapy. Cycle 1 of therapy is 6 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks plus gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks plus gemcitabine administered on Mondays, Days 7, 14 and 21. Response will be assessed after Cycle 2 (10 weeks) and patients who continue onto Cycles 2-12 will be assessed every 2 cycles (8 weeks). Patients will continue BPM31510 in combination with gemcitabine, for a maximum of 12 cycles in the absence of intolerable toxicity and progression. If gemcitabine is discontinued due to chemotherapy-related toxicity, patients may continue to receive BPM31510 as monotherapy. Patients who experience disease progression but are, in the opinion of the investigator, receiving clinical benefit may continue BPM31510 as a monotherapy or in combination with gemcitabine or as a monotherapy pending approval from the Sponsor.

Pancreatic Cancer

DRUG: BPM31510 Nanosuspension Injection
DRUG: Gemcitabine

BPM31510IV-05

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2015-11-19	Results First Submitted 2024-04-05	Last Update Submitted that met QC Criteria 2025-03-06
First Submitted that Met QC Criteria 2016-01-07	Results First Submitted that Met QC Criteria 2025-03-06	Last Update Posted (ACTUAL) 2025-03-26
First Posted (ACTUAL) 2016-01-08	Results First Posted 2025-03-26	Last Verified 2025-03

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: BPM31510 plus gemcitabine BPM31510 Nanosuspension Injection (40 mg/mL) starting dose of 110 mg/kg administered IV over 144 hours as 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). Starting on Day 21-treatment with gemcitabine IV once weekly at a start	DRUG: BPM31510 Nanosuspension Injection DRUG: Gemcitabine
EXPERIMENTAL: BPM31510 monotherapy BPM31510 Nanosuspension Injection (40 mg/mL) starting dose of 110 mg/kg administered IV over 144 hours as 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday).	DRUG: BPM31510 Nanosuspension Injection

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: BPM31510 plus gemcitabine

BPM31510 Nanosuspension Injection (40 mg/mL) starting dose of 110 mg/kg administered IV over 144 hours as 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). Starting on Day 21-treatment with gemcitabine IV once weekly at a start

DRUG: BPM31510 Nanosuspension Injection

DRUG: Gemcitabine

EXPERIMENTAL: BPM31510 monotherapy

BPM31510 Nanosuspension Injection (40 mg/mL) starting dose of 110 mg/kg administered IV over 144 hours as 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday).

DRUG: BPM31510 Nanosuspension Injection

Primary Outcome Measures	Measure Description	Time Frame
Treatment Response	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. (the appearance of new lesions is also considered progression); Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Overall Response (OR) = CR + PR	10 weeks (End of Cycle 2)

Secondary Outcome Measures	Measure Description	Time Frame
Overall Survival (OS)	Overall Survival is defined as the number of months from the first dose of study drug to the date of death due to any cause.	Up to study completion, an average of 1 year
Time to Progression (TTP)	Time to Progression is defined as tumor progression measured from the first dose of study drug to the first documentation of progression.	Day 1, End of Cycle 2 (10 weeks) and every 2 cycles (every 8 weeks) through study completion, an average of 1 year
Progression Free Survival (PFS)	The number of months from the first dose of study drug to the first documentation of progression or death due to any cause.	Up to study completion, an average of 1 year

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

The patient has a histologically or cytologically confirmed metastatic pancreatic adenocarcinoma.
The patient has undergone at least one prior, but no more than 2 prior standard, therapies for pancreatic cancer.If the patient has had prior gemcitabine treatment, the last date of gemcitabine administration-should be > 3 months prior to screening for the study. All patients who have previously received gemcitabine should be discussed with the medical monitor during screening
The patient is at least 18 years old.
The patient has an Eastern Cooperative Oncology Group (ECOG) performance status
Measurable tumor lesions according to RECIST 1.1 criteria (Section 10.2).
In the opinion of the Investigator, the patient has a life expectancy of > 3 months.
Sexually active patients and their partners agree to use an accepted method of contraception during the course of the study (Appendix C:Guidelines Regarding Women of Childbearing Potential).
Female patients of childbearing potential must have a negative pregnancy test within 1 week prior to beginning study treatment.
The patient has adequate organ and marrow function as follows:

absolute Neutrophil Count (ANC) ≥ 1500 mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL,
serum creatinine < upper limit of normal (ULN);
total bilirubin < 1.5 X (ULN) ; alanine aminotransferase (ALT), aspartate transaminase (AST) ≤ 2.5 times the upper limit of normal (ULN) if no liver involvement or ≤ 5 times the upper limit of normal with liver involvement.
The patient has serum electrolytes (including calcium, magnesium, phosphorous, sodium and potassium) within normal limits (supplementation to maintain normal electrolytes is allowed).
The patient has adequate coagulation: prothrombin time (PT) and an International Normalized Ratio (INR), and partial thromboplastin time (PTT) ≤ 1.5 times the upper limit of normal (ULN),
In the opinion of the Investigator, the patient is capable of understanding and complying with the protocol and has signed the informed consent document.

The patient has uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure (NYHA class III and IV), uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
The patient has active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, unstable angina pectoris, or uncontrolled congestive heart failure (NYHA class III and IV).
The patient has received chemotherapy or radiotherapy within 4 weeks or has received nitrosoureas or mitomycin C within 6 weeks prior to the first dose of study drug.
The patient has received radiation to ≥ 25% of his or her bone marrow within 4 weeks of the first dose of study drug.
The patient has received an investigational drug within 30 days of the first dose of study drug.
Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
History of other malignancies (except adequately treated Stage 1 cancer, cured basal cell carcinoma, superficial bladder cancer, Breast ductal carcinoma in situ (DCIS), or carcinoma in situ of the cervix) unless documented free of cancer for ≥5 years.
The patient has not recovered to grade ≤ 1 from adverse events (AEs) due to investigational drugs or other medications, which were administered more than 4 weeks prior to the first dose of study drug.
The patient is pregnant or lactating.
The patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM31510 on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.
The patient has an inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator or designee.
The patient is receiving digoxin, digitoxin, lanatoside C or any type of digitalis alkaloids.
The patient has uncontrolled or severe coagulopathies or a history of clinically significant bleeding within the past 6 months, such as hemoptysis, epistaxis, hematochezia, hematuria, or gastrointestinal bleeding.
The patient has a known predisposition for bleeding such as von Willebrand's disease or other such condition.
The patient requires therapeutic doses of any anticoagulant, including low molecular weight heparin (LMWH). Concomitant use of warfarin, even at prophylactic doses, is prohibited.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Ramesh K Ramanathan, MD, Mayo Clinic

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record